FGF2 and small cell lung carcinoma: On the other hand, in SCLC, small‐molecule antagonist MG624 showed promise through inhibition of angiogenesis and proliferation of tumors through α7 nAChRs, and subsequently, suppression of nicotine‐evoked fibroblast growth factor 2 (FGF2) [137, 138].